No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis

被引：180
|
作者：
Strober, B. E. [1 ,2 ]
Langley, R. G. B. [3 ]
Menter, A. [4 ]
Magid, M. [5 ]
Porter, B. [6 ]
Fox, T. [7 ]
Safi, J., Jr. [6 ]
Papavassilis, C. [7 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT 06030 USA
[2] Prob Med Res, Waterloo, ON, Canada
[3] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[4] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA
[5] UT Austin, Seton Family Hosp, Dept Psychiat, Austin, TX USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 178卷 / 02期
关键词：
POPULATION-BASED-COHORT;
D O I：
10.1111/bjd.16051
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E105 / E107
页数：3
相关论文
共 50 条
  • [41] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    Pariser, David
    Frankel, Ellen
    Schlessinger, Joel
    Poulin, Yves
    Vender, Ronald
    Langley, Richard G.
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    DERMATOLOGY AND THERAPY, 2018, 8 (01) : 17 - 32
  • [42] Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
    Cook-Bolden, Fran E.
    Hebert, Adelaide A.
    Guenthner, Scott T.
    Kang, Robert
    Martin, Gina
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 747 - 754
  • [43] Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies
    Galluzzo, Marco
    Talamonti, Marina
    Manfreda, Valeria
    Silvaggio, Dionisio
    Tartaglia, Chiara
    Roberto, Denis
    Campione, Elena
    Bianchi, Luca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 191 - 200
  • [44] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
    Pinter, A.
    Strober, B.
    Rosmarin, D.
    Gisondi, P.
    Vanvoorden, V.
    Peterson, L.
    Madden, C.
    de Cuyper, D.
    Warren, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
  • [45] Efficacy of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of 3 randomised controlled studies at weeks 12 and 28
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Kimball, A.
    Tyring, S.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitzs, N.
    Greens, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 109
  • [46] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [47] BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Suzuki, C.
    Lopes, N.
    VALUE IN HEALTH, 2017, 20 (09) : A891 - A891
  • [48] Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study
    Gottlieb, Alice B.
    Merola, Joseph F.
    Reich, Kristian
    Behrens, Frank
    Nash, Peter
    Bao, Weibin
    Pellet, Pascale
    Pricop, Luminita
    McInnes, Iain B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB92 - AB92
  • [49] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [50] Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
    Deodhar, A.
    Mease, P. J.
    McInnes, I. B.
    Baraliakos, X.
    Reich, K.
    Blauvelt, A.
    Leonardi, C.
    Porter, B.
    Gupta, A. Das
    Widmer, A.
    Pricop, L.
    Fox, T.
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
12345